Aniridia is a devastating ocular disease requiring intensive eye care, social and community support from birth and throughout an individual’s lifetime.

Recent News

© 2019 Aniridia-net.eu – University of Cologne – Webdesign by Effect Group Ltd.

News

Home > News (Page 3)

01 Apr 2021

Posted at 18:01h in news by
4 Likes

Organized by Aniridia Europe, with the participation of COST Action ANIRIDIA-NET Chair Prof. Neil Lagali (from the University of Linköping, Sweden) and Vice Chair Prof. Dr Claus Cursiefen (from the University of Cologne, Germany), this live webinar presented the goals and strategies of the ANIRIDIA-NET COST Action, as well as the most significant steps being taken to improve treatment and stimulate research in this disease. Comprising members from over 30 countries in Europe and beyond, ANIRIDIA-NET is the biggest research network focusing on aniridia in the world. This action brings together a critical mass of researchers, physicians, patient organizations, and other interested parties to focus on improving the lives of aniridia patients and families. A consensus guideline on current best practices for the treatment of aniridia patients; a novel keratopathy grading system...

19 Mar 2021

Posted at 18:30h in news by
5 Likes

A budget of 1.4 million € has been recently granted by the EJP RD (for European Joint Research Program on Rare Diseases) to continue to push forward research on the treatment of aniridia-associated keratopathy (AAK), which is the most difficult part of the disease to treat. The AAK-INSIGHT project was proposed by a consortium of researchers from several countries, led by Prof. Neil Lagali (Linköping University, Sweden) and Prof. Daniel Aberdam (CNRS, Biologie, Inserm-Technion, France). The AAK-INSIGHT project aims to implement a drug development program for a gene therapy medicinal product for aniridia-associated keratopathy, eventually leading to the approval of a first-in-human clinical trial. The research consortium comprises 6 active members of AniridiaNet #CA18116 Action connecting research initiatives across Europe...

26 Feb 2021

Posted at 07:09h in news by
5 Likes

AniridiaNet #CA18116 action in cooperation with Aniridia Europe are happy to present this short awareness video, hoping it may help understand this rare and complex eye disorder, while INSPIRING RESEARCH efforts in the hopes of improving its diagnosis and treatment. Aniridia patients are unique, help us shape their future! Share this video and SUPPORT the community! Our special thank you to Dr. Christina Grupcheva from Medical University of Varna @MU_Varna_Press, @ScitoonsSpain, and the patients and families involved in the production of this video. ...

21 Nov 2020

Posted at 19:33h in meetings, news by
4 Likes

On the 26th of October AniridiaNet COST Action CA#18116 members connected for the action’s 4th MC meeting taking place fully online. A highly successful meeting that gathered ophthalmologist, researchers, industry and patient’s organizations members from 22 countries. Thank all the members for their enthusiastic participation in discussing the current progress of the action and stimulating a closer collaboration for improved understanding of aniridia and related eye disorders. ...

21 Nov 2020

Posted at 17:56h in news, STSMs by
4 Likes

Dr. Gerard Boix Lemonche, a postdoctoral researcher from the University of Udine (Italy), recently returned from a scientific mission in the research group of Prof. Petrovski at the Center for Eye Research of the University of Oslo, Norway. The purpose of this fruitful mission was for him to gain hands-on technical experience in the production of bioengineered 3D corneal scaffolds, as well as in the isolation of corneal stromal and limbal epithelial stem cells from leftover donor corneas. This training provided Dr. Boix Lemonche with the expertise for developing of 3D corneal models and stablished the basis for future collaborations among both participating institutions. This scientific mission was made possible thanks to Aniridia-net CA18116 COST action networking tools. Representative...